Get to know our clinical trials
Ensayo Clínico de BMS-986453, linfocitos T con receptor antigénico quimérico (CAR) con diana doble de BCMAxGPRC5D en sujetos con mieloma múltiple en recaída o refractario
THE OBJECTIVE OF THIS STUDY IS TO ASSESS WHETHER BMS-986453 IS SAFE AND EFFECTIVE FOR TREATING PEOPLE WHOSE MULTIPLE MYELOMA (MM) HAS RECURRED AFTER PREVIOUS TREATMENT (RELAPSED) OR WHO HAVE MM THAT IS NOT RESPONDING TO CURRENT TREATMENT (REFRACTORY).
Technical Summary
- PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF BMS-986453, CHIMERIC ANTIGENIC RECEPTOR (CAR) T LYMPHOCYTE DUAL-TARGETING BCMAXGPRC5D IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA.
- Code EudraCT: 2023-506003-26
- Protocol number: CA119-0002
- Promoter: Celgene Corporation
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Who can participate?
Clinical Trial of BMS-986453, chimeric antigenic receptor (CAR) T-lymphocytes with dual targeting of BCMAxGPRC5D in subjects with relapsed or refractory multiple myeloma.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.